Price$116.64+1.97 (+1.71%)
01:30 PM07:45 PM
News · 26 weeks86+75%
2026-03-012026-08-23
Mix3090d
- Other12(40%)
- Insider9(30%)
- SEC Filings4(13%)
- Earnings2(7%)
- Analyst2(7%)
- Dividends1(3%)
Latest news
25 items- SECAbbott Laboratories filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - ABBOTT LABORATORIES (0000001800) (Filer)
- PRAbbott reaches agreements to resolve a portion of litigation involving its specialty formulas for preterm infantsAgreements will resolve the Gill case and claims involving approximately 2,000 other individualsAbbott and the medical community stand by the safety of preterm infant formulasRegulators and medical professionals recognize that these products are safe and necessary, and there is no reliable scientific evidence that they cause necrotizing enterocolitisABBOTT PARK, Ill., Aug. 20, 2026 /PRNewswire/ -- Abbott (NYSE:ABT) has reached agreements with three law firms to resolve the Gill case and claims involving approximately 2,000 other individuals relating to the company's specialty formulas for preterm infants. In July 2024, a St. Louis jury awarded the plaintiff in the Gill case $495 million in d
- PRAbbott and NACHC launch nationwide Food for Health initiative to make nutritious food a core part of healthcareThe NACHC and Abbott Food for Health Initiative is a multi-year "food is medicine" effort to support the integration of nutrition as a foundational component of primary care provided by Community Health Centers (CHCs) across the countryCertification program alongside training and resources are designed to help health centers offer real-world approaches that provide healthy food and support to prevent and manage chronic diseasesInitiative will reach 1,500+ CHCs providing affordable, comprehensive, effective care to 52.3 million people, including 1 in 7 Americans and 1 in 3 in rural AmericaABBOTT PARK, Ill. and BETHESDA, Md., Aug. 17, 2026 /PRNewswire/ -- Abbott (NYSE:ABT) and the National Ass
- INSIDEREXECUTIVE VICE PRESIDENT Morrone Louis H. sold $642,506 worth of Common shares without par value (5,850 units at $109.83), decreasing direct ownership by 8% to 70,724 units (SEC Form 4)4 - ABBOTT LABORATORIES (0000001800) (Issuer)
- ANALYSTAbbott Labs upgraded by Wolfe Research with a new price targetWolfe Research upgraded Abbott Labs from Peer Perform to Outperform and set a new price target of $130.00
- PRAbbott and Big Ten bring back 'We Give Blood' as U.S. faces blood supply crisis"We Give Blood" brings together all 18 Big Ten® schools in a competition to drive the most blood donations and win $1 million from global healthcare company AbbottFor only the second time in its history, the American Red Cross has declared a national blood crisis after donations dropped to a four-year summer low, threatening the availability of lifesaving blood for patients across the countryAbbott and the Big Ten urge people to donate blood now and will count those early donations toward the competition, which officially kicks off Aug. 26Anyone can donate blood anywhere in the U.S. between Aug. 12-Dec. 4 and log their donation starting Aug. 26 for a Big Ten school at BigTen.org/Abbott or by
- PRAbbott and Google launch first-of-its-kind partnership to transform everyday health through glucose insights and AIMulti-year collaboration combines ongoing glucose insights from Abbott's Lingo biowearable with Google Health's technology to create a more comprehensive view of personal healthPartnership includes a large-scale research study to better inform artificial intelligence (AI) coaching available in the Google Health app and future Lingo product featuresLingo, Abbott's over-the-counter continuous glucose monitor (CGM), helps people understand the impact of nutrition, activity, sleep and stress on their glucose so they can make meaningful lifestyle changesABBOTT PARK, Ill., Aug. 11, 2026 /PRNewswire/ -- Abbott (NYSE:ABT) today announced a first-of-its-kind partnership with Google Health to redefine
- SECSEC Form 10-Q filed by Abbott Laboratories10-Q - ABBOTT LABORATORIES (0000001800) (Filer)
- PRFDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.– Approval expands colorectal cancer screening options for the up to 60 million Americans who are overdue for screening – – Medicare coverage and American Cancer Society guidance support broader access to blood-based colorectal cancer screening – BRISBANE, Calif. and ABBOTT PARK, Ill., July 27, 2026 (GLOBE NEWSWIRE) -- Freenome, Inc. (NASDAQ:FRNM), an early cancer detection company developing blood-based screening tests, and Abbott (NYSE:ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved SimpleScreen™ CRC, a new blood-based screening option for colorectal cancer (CRC) in adults 45 and older who are at average risk for the disease. Abbott will exclusively
- SECAbbott Laboratories filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - ABBOTT LABORATORIES (0000001800) (Filer)
- PRAbbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS GuidanceSecond-quarter reported sales growth of 13.0 percent; comparable sales growth of 4.8 percentSecond-quarter GAAP diluted EPS of $0.53; adjusted diluted EPS of $1.31Abbott reaffirms full-year 2026 comparable sales growth guidance of 6.5% to 7.5%¹Abbott raises full-year 2026 adjusted diluted EPS guidance range to $5.45 to $5.60, compared to previous range of $5.38 to $5.58Abbott returned $2.1 billion to shareholders in the second quarter in the form of dividends and share repurchasesABBOTT PARK, Ill., July 16, 2026 /PRNewswire/ -- Abbott (NYSE:ABT) today announced financial results for the second quarter ended June 30, 2026. Second-quarter sales increased 13.0 percent on a reported basis and 4.
- INSIDERSEC Form 4 filed by Director Stratton John G4 - ABBOTT LABORATORIES (0000001800) (Issuer)
- INSIDERSEC Form 4 filed by Director Roman Michael F4 - ABBOTT LABORATORIES (0000001800) (Issuer)
- INSIDERSEC Form 4 filed by Director Gonzalez Patricia Paola4 - ABBOTT LABORATORIES (0000001800) (Issuer)
- INSIDERSEC Form 4 filed by Director Conroy Kevin T4 - ABBOTT LABORATORIES (0000001800) (Issuer)
- INSIDERSEC Form 4 filed by Director Ahuja Nita4 - ABBOTT LABORATORIES (0000001800) (Issuer)
- INSIDEREXECUTIVE VICE PRESIDENT Morrone Louis H. covered exercise/tax liability with 269 units of Common shares without par value, decreasing direct ownership by 0.35% to 76,574 units (SEC Form 4)4 - ABBOTT LABORATORIES (0000001800) (Issuer)
- ANALYSTRobert W. Baird initiated coverage on Abbott Labs with a new price targetRobert W. Baird initiated coverage of Abbott Labs with a rating of Outperform and set a new price target of $121.00
- INSIDEREVP, GC AND SECRETARY Cushman Elizabeth C. covered exercise/tax liability with 560 units of Common shares without par value, decreasing direct ownership by 1% to 38,013 units (SEC Form 4)4 - ABBOTT LABORATORIES (0000001800) (Issuer)
- PRAbbott hosts conference call for second-quarter earningsABBOTT PARK, Ill., June 25, 2026 /PRNewswire/ -- Abbott (NYSE:ABT) will announce its second-quarter 2026 financial results on Thursday, July 16, before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day.About Abbott: Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical
- PRALZpath Signs Global Licensing Agreement with Abbott to Advance Blood-Based Alzheimer's Disease TestingALZpath Strengthens Market Leadership with Abbott Agreement to Help Enable Early Alzheimer's Diagnosis at Global Scale CARLSBAD, Calif., June 24, 2026 /PRNewswire/ -- ALZpath Inc., the leader in blood test-based diagnostic solutions for Alzheimer's disease, today announced a licensing agreement with Abbott (NYSE:ABT), a global healthcare leader, to incorporate ALZpath's proprietary phosphorylated Tau 217 (pTau217) antibody into the development of an in vitro diagnostic (IVD) test for Alzheimer's disease. The test would be designed for use on Abbott's Alinity ci-series systems, which represents one of the largest install bases of immunoassay instruments worldwide. ALZpath's pTau217 antibody i
- INSIDERDirector Stratton John G bought $173,640 worth of Common shares without par value (2,000 units at $86.82), increasing direct ownership by 9% to 23,319 units (SEC Form 4)4 - ABBOTT LABORATORIES (0000001800) (Issuer)
- SECSEC Form 11-K filed by Abbott Laboratories11-K - ABBOTT LABORATORIES (0000001800) (Filer)
- PRAbbott declares 410th consecutive quarterly dividendABBOTT PARK, Ill., June 12, 2026 /PRNewswire/ -- The board of directors of Abbott (NYSE:ABT) today declared a quarterly common dividend of 63 cents per share. This marks the 410th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable Aug. 17, 2026, to shareholders of record at the close of business on July 15, 2026.Abbott has increased its dividend payout for 54 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have increased dividends annually for at least 25 consecutive years.About Abbott:Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of
- PRNew research shows even stronger health outcomes for participants in a 'Food is Medicine' program when paired with support from community health workersStudy at ADA's Scientific Sessions shows participants in Abbott's Healthy Food Rx program combined with health coaching had significant health improvementsAbbott's Healthy Food Rx program is a Food is Medicine initiative delivering recipe-based food boxes and nutrition education to people living with diabetesNEW ORLEANS, June 8, 2026 /PRNewswire/ -- New research presented at the American Diabetes Association's 86th Scientific Sessions showed that adults living with type 2 diabetes participating in Abbott's (NYSE:ABT) Healthy Food Rx "Food is Medicine" program, paired with community health worker–led coaching, experienced major improvements in healthy eating, physical activity, diabetes self-
ABT FAQ
7 questionsWhat does Abbott Laboratories do?
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo...Where does ABT stock trade?
Abbott Laboratories (ABT) is listed on NYSE.What sector and industry is ABT in?
Abbott Laboratories operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.Does ABT pay a dividend?
ABT's most recent ex-dividend date was 2026-07-15 with a cash dividend of $0.63 per share. No future ex-date is on file yet.What are analysts saying about ABT?
Abbott Laboratories has had 8 recent analyst actions on file. The most recent action was from Wolfe Research: Outperform on 2026-08-13.What companies are similar to ABT?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ABT side-by-side with any of them on Quantisnow.How can I track ABT on Quantisnow?
Quantisnow aggregates Abbott Laboratories's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ABT to receive live email and push alerts on every new disclosure.